Sivik Global Healthcare
GREENWICH, CTfiles as Sivik Global Healthcare LLC
$132m in 34 US stocks at the end of 30 June 2026. The top 10 are 46.6% of the money. It changed about 0.0% of the portfolio this quarter.
Value
$132m
Stocks
34
Top 10 share
46.6%
Turnover
0.0%
What changed this quarter
New
Bought for the first time this quarter.
None this quarter.
Added
Bought more of a stock they already held.
None this quarter.
Cut
Sold some of their stake.
None this quarter.
Sold out
Sold their entire stake.
None this quarter.
Holdings
- Spdr Series TrustXBI
- Share
- 14.5%
- Value
- $19m
- Shares
- 150,000
Held
- Call- BSX 100 @ 75 EXP 04/17/2026
- Share
- 3.8%
- Value
- $5m
- Shares
- 800
Held
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Spdr Series TrustXBI | 14.5% | $19m | 150,000 | Held |
| Cardinal HealthCAH | 3.9% | $5m | 24,000 | Held |
| Call- BSX 100 @ 75 EXP 04/17/2026 | 3.8% | $5m | 800 | Held |
| Johnson & JohnsonJNJ | 3.7% | $5m | 20,000 | Held |
| MerckMRK | 3.7% | $5m | 40,000 | Held |
| CencoraCOR | 3.6% | $5m | 15,000 | Held |
| Eli LillyLLY | 3.5% | $5m | 5,000 | Held |
| WatersWAT | 3.4% | $4m | 15,000 | Held |
| Vertex PharmaceuticalsVRTX | 3.4% | $4m | 10,000 | Held |
| Intuitive SurgicalISRG | 3.2% | $4m | 9,000 | Held |
| AstrazenecaAZN | 3.0% | $4m | 20,000 | Held |
| Thermo Fisher ScientificTMO | 3.0% | $4m | 8,000 | Held |
| Boston ScientificBSX | 3.0% | $4m | 62,000 | Held |
| DanaherDHR | 2.9% | $4m | 20,000 | Held |
| Tenet HealthcareTHC | 2.9% | $4m | 20,000 | Held |
| Gilead SciencesGILD | 2.6% | $3m | 25,000 | Held |
| HumanaHUM | 2.6% | $3m | 20,000 | Held |
| Mettler Toledo InternationalMTD | 2.6% | $3m | 2,750 | Held |
| MckessonMCK | 2.6% | $3m | 4,000 | Held |
| Agilent TechnologiesA | 2.6% | $3m | 30,000 | Held |
| StrykerSYK | 2.5% | $3m | 10,000 | Held |
| AbbVieABBV | 2.5% | $3m | 15,000 | Held |
| Universal Health ServicesUHS | 2.4% | $3m | 17,500 | Held |
| Regeneron PharmaceuticalsREGN | 2.3% | $3m | 4,000 | Held |
| Bio-Rad LaboratoriesBIO | 2.1% | $3m | 10,000 | Held |
| BiogenBIIB | 2.1% | $3m | 15,000 | Held |
| UnitedHealth GroupUNH | 2.1% | $3m | 10,000 | Held |
| Globus MedicalGMED | 2.0% | $3m | 30,000 | Held |
| Abbott LaboratoriesABT | 1.9% | $3m | 25,000 | Held |
| Edwards LifesciencesEW | 1.2% | $2m | 20,000 | Held |
| Smith & NephewSNN | 1.2% | $2m | 50,000 | Held |
| Elevance HealthELV | 1.1% | $1m | 5,000 | Held |
| Encompass HealthEHC | 1.1% | $1m | 15,000 | Held |
| CVS HealthCVS | 1.1% | $1m | 20,000 | Held |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is down 41.1% since 30 June 2025.
Where the money is
Health care81.6%
Other18.4%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.